Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

By The Northwire Desk — AI Analysis Jun 22, 2026 · 08:30 QNTM · 5.4 Quantum BioPharma Ltd.
Executive Summary
  • Quantum BioPharma announced that its lead candidate, Lucid-MS (Lucid-21-302), is advancing toward Phase 2 clinical trials for multiple sclerosis.
  • The company completed Phase 1 single and multiple ascending dose studies in healthy volunteers, reporting no safety or tolerability issues.
  • An Investigational New Drug (IND) application was formally submitted to the FDA in April 2026, following the completion of 180-day oral toxicity and toxicokinetic studies in late 2025.
  • Strategic partnerships were secured: a binding letter of intent with Allucent (CRO) for Phase 2 execution, a CDMO for manufacturing, and a diagnostic imaging collaboration with Massachusetts General Hospital to validate a PET tracer for myelin integrity.
  • The drug utilizes a first-in-class, non-immunomodulatory mechanism targeting the myelin sheath directly, aiming to prevent and reverse demyelination.
Material Impact
  • The release confirms incremental progress toward Phase 2 but introduces no fundamentally new data or unexpected catalysts.
  • The market had already priced in the IND submission and CRO partnership during the March-April 2026 news cycle. The stock's subsequent rally to $13.00 in May has since retraced to $5.43, indicating the market views this update as expected.
  • A critical contextual risk remains: a June 1, 2026 release explicitly stated the FDA placed the IND on clinical hold on May 28, 2026, and withdrew all prior timelines. The June 22 release does not explicitly confirm the hold has been lifted, only that the IND was submitted in April and the company is "advancing toward Phase 2." This ambiguity tempers the positive headline.
  • Financially, the company reported a Q1 2026 net loss of $13.75 million and negative book value per share (-$0.24). While operating cash burn decreased to $1.66 million, the negative equity and reliance on digital asset valuations create a fragile capital structure.
QNTM · Price
Company Overview
  • Quantum BioPharma Ltd. (NASDAQ: QNTM) is a pre-revenue biopharmaceutical company focused on neurodegenerative and metabolic disorders.
  • Core asset: Lucid-MS (Lucid-21-302), a patented first-in-class oral therapy targeting myelin degradation in multiple sclerosis.
  • Secondary assets: unbuzzd (a clinically validated hangover remedy licensed to Unbuzzd Wellness Inc., with Quantum holding a 19.84% stake and royalty rights), and Qlarity (a natural health product with a Health Canada license).
  • Corporate strategy includes treasury diversification into digital assets and pursuing a $700 million securities litigation against major Canadian banks for alleged market manipulation.
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other May 07, 2026 · 07:00

Quantum BioPharma Extends Runway on Crypto Gains as Lucid-MS Enters Phase 2

Earnings